title: Administration of recombinant human GHRH-1,44-amide for 3 months reduces abdominal visceral fat mass and increases physical performance measures in postmenopausal women.
abstract: OBJECTIVE
  A recent study indicated that twice-daily s.c. administration of a high dose of recombinant human GHRH-1,44-amide (GHRH) for 90 days can alter body composition in healthy older men. No data establish whether this is also true in postmenopausal women. The present study tests the hypothesis that the same GHRH regimen applied in women will: (i) elevate both IGF-I and GH concentrations; and (ii) reduce abdominal visceral fat mass, augment total body water and enhance functional performance.
  
  
  METHODS
  Ten postmenopausal volunteers underwent baseline study and then received 1 mg GHRH twice daily s.c. for 3 months.
  
  
  METHODS
  Statistical comparisons were made with pre-intervention baseline data.
  
  
  RESULTS
  GHRH administration stimulated: (i) a mean 98 +/- 14% elevation of overnight GH concentrations after administration of the peptide for 1 and 3 months (P < 0.005); (ii) a sustained 71 +/- 3.5% rise in IGF-I concentrations over the interval from 2 weeks to 3 months (P < 0.0012); (iii) a 16 +/- 7% reduction in abdominal visceral fat mass (P = 0.029) and a 14 +/- 5% increase in tri-tiated water space (P < 0.025); (iv) an abbreviation of the times required to walk 30 m (P = 0.015) and ascend two flights of stairs (P = 0.003). Most (70%) subjects experienced local skin reactivity. There were no systemic adverse events.
  
  
  CONCLUSIONS
  A 3-month regimen of GHRH supplementation in postmenopausal women can stimulate GH and IGF-I production, reduce abdominal visceral fat and improve selected measures of physical performance, while inducing significant local skin reactivity.
authors.affiliation: Division of Endocrinology and Metabolism, Department of Internal Medicine, General Clinical Research Center, Mayo School of Graduate Medical Education, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA. veldhuis.johannes@mayo.edu
authors.forename: Johannes D
authors.initials: JD
authors.lastname: Veldhuis
authors.forename: James M
authors.initials: JM
authors.lastname: Patrie
authors.forename: Kirsten
authors.initials: K
authors.lastname: Frick
authors.forename: Judith Y
authors.initials: JY
authors.lastname: Weltman
authors.forename: Arthur L
authors.initials: AL
authors.lastname: Weltman
mesh_terms: D050153:Abdominal Fat / Q000187:drug effects*; D000368:Aged; D004334:Drug Administration Schedule; D004487:Edema / Q000139:chemically induced; D005260:Female; D013007:Growth Hormone-Releasing Hormone / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007279:Injections, Subcutaneous / Q000009:adverse effects; D008875:Middle Aged; D010809:Physical Fitness; D017698:Postmenopause; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D012871:Skin Diseases / Q000139:chemically induced; D014781:Viscera; D016138:Walking
chemical_list: D011994:Recombinant Proteins; D013007:Growth Hormone-Releasing Hormone